SCHEMBL3265544

SCHEMBL3265544

Cc1ccc(N2CCC(CNC(=O)OCC(N)=O)CC2)nn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CKS1B P61024 4/20 0.41
SKP1 P63208 4/20 0.41
SKP2 Q13309 4/20 0.41
ACACB O00763 5/20 0.41
ACACA Q13085 5/20 0.41
TPSAB1 Q15661 1/20 0.39
TPSD1 Q9BZJ3 1/20 0.39
TPSG1 Q9NRR2 1/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 2/20 0.38
LMNA P02545 2/20 0.38
GAA P10253 2/20 0.38
MAPT P10636 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3270022 0.89 SCD (0.43) MEN1KMT2ASMN1; SMN2TPSAB1TPSD1
SCHEMBL3266209 0.85 CKS1B (0.44) CKS1BSKP1SKP2ACACBACACA
SCHEMBL3265598 0.84 CKS1B (0.46) CKS1BSKP1SKP2
SCHEMBL1728825 0.82 CKS1B (0.47) MEN1KMT2ASMN1; SMN2CKS1BSKP1
SCHEMBL3269967 0.82 F10 (0.49) SMN1; SMN2CKS1BSKP1SKP2ACACB
SCHEMBL3266247 0.81 HRH3 (0.46) KMT2ASMN1; SMN2CKS1BSKP1SKP2
SCHEMBL3269155 0.81 CHIT1 (0.42) KMT2ACKS1BSKP1SKP2TPSAB1
SCHEMBL3265671 0.81 DEGS1 (0.49) CKS1BSKP1SKP2KDM4EMAPT
SCHEMBL3268968 0.80 ACACB (0.49) CKS1BSKP1SKP2ACACBACACA
SCHEMBL3270016 0.78 ALDH1A1 (0.46) CKS1BSKP1SKP2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MEN1 1340/4885KMT2A 2458/4885SMN1; SMN2 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.